Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

250.91
+2.130.86%
Pre-market: 252.481.57+0.63%09:18 EDT
Volume:3.87M
Turnover:967.41M
Market Cap:443.45B
PE:70.88
High:251.18
Open:247.73
Low:246.77
Close:248.78
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.91
T/O Rate:0.22%
Dividend:6.83
Dividend Rate:2.72%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-74.72
PE(LYR):106.32

Loading ...

AbbVie Closes $10.9B Apogee Deal — Accretion Not Until 2032

Bellwether Stocks Movement
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Reuters
·
Sep 03

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS
·
Sep 03

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS
·
Sep 03

AbbVie to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Allergan Aesthetics Unveils Layered Beauty Report on Global Shift Toward Personalized Aesthetic Care

Reuters
·
Sep 02

AbbVie Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 02

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

NetraMark Appoints Abivax Regulatory Chief Keith Fournier to Board

Reuters
·
Sep 01